Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

BACKGROUND: Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 (CV9202) is an active cancer immunotherapeutic comprising protamine-formulated, sequence-optimized mRNA encoding six non-smal...

Descripción completa

Detalles Bibliográficos
Autores principales: Papachristofilou, Alexandros, Hipp, Madeleine M., Klinkhardt, Ute, Früh, Martin, Sebastian, Martin, Weiss, Christian, Pless, Miklos, Cathomas, Richard, Hilbe, Wolfgang, Pall, Georg, Wehler, Thomas, Alt, Jürgen, Bischoff, Helge, Geißler, Michael, Griesinger, Frank, Kallen, Karl-Josef, Fotin-Mleczek, Mariola, Schröder, Andreas, Scheel, Birgit, Muth, Anke, Seibel, Tobias, Stosnach, Claudia, Doener, Fatma, Hong, Henoch S., Koch, Sven D., Gnad-Vogt, Ulrike, Zippelius, Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368815/
https://www.ncbi.nlm.nih.gov/pubmed/30736848
http://dx.doi.org/10.1186/s40425-019-0520-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368815/
https://www.ncbi.nlm.nih.gov/pubmed/30736848
http://dx.doi.org/10.1186/s40425-019-0520-5

Ejemplares similares